Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03146013 · ClinicalTrials.gov registry record
Dual Algorithm Post Market Clinical Study
A clinical trial, sponsored by MP Biomedicals.
- Completed
- Registry status
- 100
- Enrollment target
NCT03146013: Completed study, sponsored by MP Biomedicals.
NCT03146013 is a clinical trial that has completed, run by MP Biomedicals. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03146013 has completed, sponsored by MP Biomedicals.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the validity and reproducibility of the MP Diagnostics HTLV Blot 2.4 in blood specimens testing repeat reactive (RR) on the first FDA licensed screening assay (Abbott Prism) and non-reactive (NR) on the second FDA licensed screening assay (Avioq ELISA).
Primary Outcome
HTLV I/II confirmation of specimens testing RR on the first FDA licensed HTLV screening assay and non-reactive (NR) on a second FDA licensed HTLV screening assay.
Interventions
- DIAGNOSTIC_TEST MP Diagnostics HTLV Blot 2.4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2017-05-31 |
What the finished NCT03146013 record still lists
NCT03146013 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which MP Diagnostics HTLV Blot 2.4 is the first listed.
NCT03146013 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03146013 about?
NCT03146013 is a clinical study titled "Dual Algorithm Post Market Clinical Study". The purpose of this study is to assess the validity and reproducibility of the MP Diagnostics HTLV Blot 2.4 in blood specimens testing repeat reactive (RR) on the first FDA licensed screening assay (Abbott Prism) and non-reactive (NR) on the second FDA licensed screening assay (Avioq ELISA).
What is the current status of trial NCT03146013?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2017-03-01. Estimated completion is 2017-05-31.
What interventions are being tested in trial NCT03146013?
The interventions under investigation include: MP Diagnostics HTLV Blot 2.4 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03146013?
This trial is sponsored by MP Biomedicals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI